CVS Faces Steepening Challenges in Its Pharmacy Benefit Management Business

Senior Equity Analyst

Julie Utterback

Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS aims to be the most customer-centric health company in the United States and has spent over a decade positioning itself as a managed care leader, with the acquisitions of pharmacy benefit manager Caremark (2007), insurance provider Aetna (2018), and healthcare service provider Oak Street (2023) defining its strategic direction. CVS' top-tier retail pharmacy, health insurer, and PBM franchises create the potential to improve health outcomes and even bend the healthcare cost curve for its clients, especially if it can align incentives by owning healthcare service providers, as well.

CVS appears uniquely positioned to improve health outcomes, and we appreciate management's focus on better leveraging its assets through digital and other means to bring a more consumer-centric approach to healthcare, which could provide many benefits. For example, management recently highlighted an observational study that showed when members use both CVS medical and pharmacy benefits, their medical costs decline 3%-6% over a three-year period through factors like fewer hospitalizations and emergency room visits. Driving savings like that would be attractive to many potential clients, like self-funded employers, and CVS' own at-risk operations, like its Medicare Advantage plans, by reducing medical costs. Also, CVS continues to dive further into healthcare services through its HealthHub strategy and recent acquisitions of primary-care assets. We think the relatively high-margin healthcare services business could eventually accelerate CVS' profit growth directly or by reducing long-term costs in its medical and pharmacy benefit businesses. 

With its integrated strategy, management aims to accelerate bottom-line growth to the low double digits on a maintainable basis in the long run, but management has pushed the target date for that back multiple times. Now, we only think that growth rate is possible with significant share repurchases toward the end middle of our explicit 10-year forecast period on mid-single-digit operating profit growth in the long run.

Business Strategy & Outlook

CVS Health earns a narrow economic moat rating from us. As a top-tier medical insurer, pharmacy benefit manager, and pharmacy retailer, we believe CVS possesses enough scale-related cost advantages to generate economic profits for the long run. Even after the late 2018 Aetna merger, which cut into returns on invested capital including goodwill, and its recent healthcare services acquisitions, we estimate that CVS' ROICs should remain above its capital costs throughout our explicit 10-year forecast period. CVS generates profits almost equally among its three major segments, and we see the medical insurance and PBM assets as generally stronger than the retail store chain. 

In medical insurance, we see two moat sources—cost advantage and network effects. An insurer’s cost advantages relate primarily to scale, both broadly and locally. The legacy Aetna operations represent the third-largest insurer that we cover, with about 26 million members, albeit a distant third in our coverage universe behind Elevance and UnitedHealth. With such significant scale in the fragmented health insurance market, we believe CVS benefits from local scale advantages in specific metropolitan markets. Local scale advantages allow for greater negotiating leverage versus service providers than smaller insurers in each community, which contributes to cost advantages in each specific location. Also, when local scale advantages are significant enough, we think CVS’ insurance operations benefit from a network effect. According to the American Medical Association, the share of local insurance markets in the U.S. that were highly concentrated grew to 75% in 2021 from 71% in 2014, with the leaders likely taking share in those markets due to local market dynamics. For example, in communities where CVS already has substantial market share, it can offer lower costs or more benefits per member to existing and potential clients than its peers. If that offering is compelling enough, more employers will be attracted to CVS’ insurance plans in those communities, and local service providers, such as hospitals and physician groups, will have more incentive to join and offer lower prices to CVS’ insurance networks to gain access to its large, growing membership rolls. As CVS’ local market share rises, its negotiating leverage with providers also rises, which can create a virtuous cycle (a network effect) where CVS attracts even more clients and more providers to its insurance network in that area. Overall, these dynamics create barriers to entry for would-be competitors, as compiling an attractively priced provider network in a new geography would be difficult without an established membership pool.

CVS’ Caremark segment provides PBM services and appears competitively advantaged in its own right with a combination of moat sources. The PBM industry has consolidated into three top players—CVS, UnitedHealth, and Cigna—controlling nearly 80% of U.S. prescription volumes on an adjusted basis, and we believe those players built their leadership on previous cost advantages. However, with limited cost advantages over each other, we see evidence of some switching costs (through contracts) and network effects now, although CVS' recent contract losses create some new uncertainty around these moat sources, in our opinion. We believe CVS’ leadership position in its PBM operations should help it generate excess returns over time. We continue to view the fixed-cost leverage associated with processing about 2 billion of the nearly 7 billion adjusted prescriptions filled annually. This consolidation of purchasing power helps CVS extract discounts from drug manufacturers on one end of the transaction and pharmacies on the other end of the transaction, which helps create value for its clients, such as insurance plans and employers, on their pharmacy cost trends. We see some switching costs in this business with contract lengths typically around three years and annual retention rates in the high 90s for all three of the top-tier PBM players. Switching the administrative activities, partner relationships, and pharmacy benefit plan specifications to a new PBM vendor can be time-consuming and onerous, which creates inertia for clients with limited realistic alternatives, in our opinion. However, switching is possible, and the loss of specific clients could constrain the firm's growth eventually, especially as new insurance competitors like Elevance, Amazon, and the Mark Cuban Cost Plus Drug Company taking aim at this market. 

CVS possesses a top-tier position in retail pharmacy stores that appears to have some positive qualities, if not a strong moat. CVS drives significant volumes through over 9,000 pharmacy locations. This large store network is attractive for pharmacy benefit managers when assembling plans to obtain volume-based discounts from pharmaceutical manufacturers, and also assembling convenient retail store locations that would be attractive to an insurance plan members. And while it trails Walgreens’ average revenue per store, CVS’ average store revenue remains significantly higher than most other U.S. pharmacies. Scale allows CVS to leverage fixed costs (such as pharmacist salaries and rent) more effectively than subscale peers, and both CVS and Walgreens continue to steal share from smaller independent pharmacies. CVS, Walgreens, and Walmart also have advantageous relationships with the top U.S. drug distributors, which may give them a mild leg up over other retail pharmacies on generic drug pricing. Beyond that, these retail store locations give CVS a unique asset that it may be able to leverage into destinations for higher-margin healthcare services, like primary care, eventually.

In terms of environmental, social, and governance issues, our narrow-moat view of CVS is informed by an analysis of potential changes to the U.S. healthcare system. The key long-term ESG risk that CVS faces, in our opinion, is how U.S. strives to reach universal, affordable coverage. While some strategies considered in recent years to reach universal coverage included eliminating the private insurance industry, those plans have largely been rejected for more moderate proposals that build on the existing healthcare system and include private insurers even in government-sponsored programs like Medicare and Medicaid. During the next 10 years, we view scenarios where CVS provides medical and pharmaceutical benefits through employers and government-sponsored programs (like Medicare Advantage and Medicaid MCOs) as much more likely than not. And overall, since the 2020 election, the impact of potential policy changes has been limited, and we suspect considered changes in the near term (such as increased regulations on the PBM) will be manageable for CVS.

Narrow

Economic Moat

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Pharmacy Services, Retail or Long-Term Care, Health Care Benefits, and Corporate and Other. The Pharmacy Services segment focuses on the pharmacy benefit management solutions. The Retail or Long-Term Care segment includes the sale of prescription drugs and an assortment of health and wellness products, and general merchandise. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, Medicare Part D prescription drug plan, Medicaid health care management services, and health information technology products and services. The Corporate and Other segment is involved in providing management and administrative services. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Campbell Soup

Verizon

CVS Health, Campbell Soup, and Verizon are all down 10% or more this year. But each of these stocks pays out over 3% in dividends at present.

3 High-Yielding Dividend Stocks That Are on Sale

Archer-Daniels-Midland Company

ConocoPhillips

Dow Inc

Energy Transfer LP Unit

Ford Motor Company

MetLife

Pfizer

Philip Morris

Southern Company

WestRock

Exxon Mobil

The June/July 2023 edition of Fortune Magazine revealed 500 biggest U.S. companies by revenue. To sniff out the best dividend buys, I focused on 68 industry leaders using YCharts 6/22/23 data. Those 68 industry leaders were segmented into 21 business sectors ranging (alphabetically) from apparel to transportation. 58 dividend yielding stocks highlighted those 68 industry leaders and ranged 0.17% to 9.71% in annual yield and ranged -48.62% to 44.50% in broker-estimated one-year price-target-upsides by YCharts 6/22/23 reckoning.

500 Top Dividend Dogs

Bristol-Myers

Thermo Fisher Scientific

CVS should benefit from rising demand for health insurance and medications. Thermo Fisher Scientific is a key provider of medical supplies to the drug industry.

3 Healthcare Stocks That Are Too Cheap to Ignore

Ally Financial

Johnson & Johnson

Over time, dividend-paying stocks tend to deliver better returns than non-dividend payers. CVS Health and Johnson & Johnson are healthcare conglomerates that dividend investors appreciate for different reasons.

3 Reliable Dividend Stocks to Buy Now and Hold Forever

CVS Health's recent acquisitions suggest it is looking to expand further into healthcare. Strong free cash flow could enable it to continue growing via acquisitions in the future.

Where Will CVS Health Be in 5 Years?

CVS Health (CVS) continues to give high priority to digital engagement, after surpassing 50 million unique digital customers in the first quarter.

CVS Health (CVS) Retail Arm Continues to Grow Amid Rising Costs

Investment will provide Portland, Maine seniors with 52 affordable housing units WOONSOCKET, R.I. , June 20, 2023 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced an $8.4 million investment with Community Housing of Maine ("CHOM"), the Portland Housing Authority and Boston Financial that will lead to the construction of 52 affordable housing units for older adults as part of the company's commitment to advancing health equity by addressing social determinants of health at the local level.

CVS Health invests $8.4 Million in Portland affordable housing

UnitedHealth Group

Health insurance stocks fell recently in response to an offhand comment from a UnitedHealth Group executive. The recent dip is an excellent opportunity to add shares of CVS Health and UnitedHealth Group to a dividend growth portfolio.

2 Beaten-Down Dividend Growth Stocks to Buy on the Dip

UnitedHealth Group's CFO outlook on higher medical costs led to a major selloff in the managed care sector, causing CVS Health's stock to plummet by 7.8% in one day. CVS' Medical Care Ratio (MCR) is expected to rise due to increased patient utilization, but the impact on future profits may not be as significant as feared. I reiterate a Strong Buy rating for CVS Health, expecting the stock to recover to its average valuation in the near future.

CVS Health: Examining The Implications Of Higher Medical Costs

CVS declined about 40% since its previous highs and is obviously facing some risks (including higher debt levels again) which led to a revised guidance. Competitor UnitedHealth is seeing challenging times ahead due to a higher medical care ratio. Despite potential short-term risks, CVS Health is a compelling growth story, and management is expecting higher earnings per share in the years to come.

CVS Health: Buy The Dip!

CVS has seen its shares decline to a pretty low price. The valuation is very undemanding. The yield is high, and the long-term outlook is solid.

CVS Health: Buy The Panic

CVS Health (CVS) to receive clean, renewable energy through a 12-year agreement with Constellation.

CVS Health (CVS) Invests in Renewable Energy With New Pact

Elevance Health Inc

Humana

Shares of UnitedHealth, Humana, Elevance Health and CVS Health all declined, while medical device manufacturers and hospital operators edged higher.

Health insurance stocks slide after UnitedHealth warns more surgeries will drive up medical costs

UnitedHealth's stock fell 7% Wednesday after saying an uptick in surgeries could squeeze revenues.

Health Insurance Stocks Tumble Over Spike In Surgeries Delayed By Pandemic

Centene

Health insurance stocks fell after a UnitedHealth Group executive's comments at a healthcare conference. UnitedHealth Group is seeing increased volumes of elective procedures for seniors.

Why Centene, CVS Health, and Humana Stocks Are Sinking Today

Constellation Energy Corp

WOONSOCKET, R.I.--(BUSINESS WIRE)--CVS Health® (NYSE: CVS) today announced an 18 megawatt agreement with Constellation (NASDAQ: CEG) to purchase zero-emission, renewable energy equivalent to the annual electricity use of its 147 CVS Health locations throughout Michigan. Through a 12-year agreement beginning in April 2025, CVS Health will purchase energy and renewable energy certificates (RECs) from Swift Current Energy's Double Black Diamond Solar Project in Illinois. This is made possible by a.

CVS Health Enters Agreement With Constellation to Purchase Renewable Energy

AllianceBernstein Hld

Arbor Realty Trust

American Tower

Ares Capital

Alexandria Real Estate Equities

BHP Billiton

British American Tobacco

Extra Space Storage

Fifth Third Bancorp

Hasbro

Navient

NexPoint Residential Trust

Vici Properties

March-April 2022, UBS, Kiplinger, and Barron's analysts/reporters listed five sets of stocks sorted as “Inflation Busters.” Those five-articles revealed 48 equities, with 43 paying-dividends. This over one-year-old list continues to beat-back new-strains-of-inflation.

11 Buyable Inflation-Busting June Dividend Stocks

CVS Heath's (CVS) MinuteClinic has an in-clinic Net Promotor Score of more than 81, putting it in the top customer rankings.

CVS Heath (CVS) MinuteClinic Earns 6th Health Care Approval

SAN DIEGO--(BUSINESS WIRE)-- #digitalpathology--XiFin announced today that Kyu Rhee, M.D., MPP, will serve as Senior Strategic Advisor to help drive acceptance for expanded payor coverage of pharmacist-provided clinical services through medical benefits and the convergence of diagnostics and therapy. Dr. Rhee serves as a physician executive across the healthcare industry, and most recently, was Senior Vice President and Aetna Chief Medical Officer at CVS Health. “Dr. Rhee is a nationally-recognized public and priv.

XiFin Enlists Former CVS Health Physician Executive in Advocacy Efforts to Advance Healthcare Access and Equity via Expanded Coverage of Pharmacy Clinical Services

MinuteClinic continues to earn Gold Seal of Approval®  from national health care evaluation and certifying agency WOONSOCKET, R.I. , June 12, 2023 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that MinuteClinic, the retail medical clinic located inside select CVS Pharmacy® stores in 36 states and Washington, D.C.

MinuteClinic® receives 6th consecutive Ambulatory Health Care Accreditation from The Joint Commission

AT&T

Stocks that pay steadily rising dividends tend to outperform stocks that don't. CVS Health's benefits management business is increasingly lucrative, because the company can directly provide more of the benefits it's paid to manage.

2 Unstoppable Dividend Growth Stocks to Buy for the Next Decade

LyondellBasell Industries

United Parcel Service and Archer-Daniels-Midland are two dividend stocks to watch in June 2023. UPS has a dividend yield of 3.78%, while ADM offers a yield of 2.45% and has a 48-year history of growing dividends. Other dividend stocks to consider include CVS Pharmacy, LyondellBasell, and Johnson & Johnson.

Dividend Stock Watch List: Lanny's June 2023 Edition

Bank of America

Lululemon Athletica

Newmont Mining

NVIDIA

The first quarter of 2023 was quite eventful for investors, marked by several major bank collapses due to insufficient preparation for the rising interest rate environment and renewed fervor for artificial intelligence stocks following the rollout of OpenAI's ChatGPT. The S&P 500 climbed 7.45% for the quarter, while the Nasdaq soared 21.34% and the Dow Jones Industrial Average was mostly flat, up just 0.41%.

The Top Guru Stock Picks of the 1st Quarter

Allergan

Teva Pharmaceutical

Walgreens

Teva, Allergan, CVS and Walgreens said enough states agreed to final agreements, adding to the billions flowing to communities.

Pharmaceutical Giants Set $19 Billion Opioid Settlement as States Debate How to Spend It

AbbVie

New York Attorney General Letitia James announced Friday the final approval of $17.3 billion in national settlement agreements with drug-store chains CVS Health Corp. CVS, and Walgreens Boots Alliance Inc. WBA, -0.68%, and with drug makers Teva Pharmaceutical Industries Ltd. TEVA, -0.61% and AbbVie Inc.'s ABBV, +0.61% Allergan.

NY AG approves $17.3 billion opioid settlement with CVS, Walgreens, Teva and AbbVie's Allergan

News for CVS Health Stock (CVS)